Showing 1 - 10 of 73
A variety of program evaluation designs are available to assess the impact of disease or care management programs, which can make it difficult to compare outcomes of different interventions. The need to compare programs has resulted in consideration of standardizing evaluations of disease...
Persistent link: https://www.econbiz.de/10005243002
Cost-effectiveness analysis has gained status over the last 15 years as an important tool for assisting resource allocation decisions in a budget-limited environment such as healthcare. Randomised (multicentre) multinational controlled trials are often the main vehicle for collecting primary...
Persistent link: https://www.econbiz.de/10005243113
Objective: There are multiple reasons for missing data in observational studies; excluding patients with missing data can lead to significant bias. In this study, we evaluated several methods for assigning missing values to health service utilisation. Design and setting: Cancer of the Prostate...
Persistent link: https://www.econbiz.de/10005243146
Persistent link: https://www.econbiz.de/10005243154
Evidence produced by multinational trial-based cost-effectiveness studies is often used to inform decisions concerning the adoption of new healthcare technologies. A key issue relating to the use of this type of evidence is the extent to which trial-wide economic results are applicable to every...
Persistent link: https://www.econbiz.de/10008725811
The debate surrounding whether the findings of efficacy studies are applicable to real-world treatment situations is ongoing. The issue of lack of applicability due to a lack of clinical heterogeneity could be addressed by employing less restrictive inclusion criteria. Given that health economic...
Persistent link: https://www.econbiz.de/10010614269
Sample size and power for cost-effectiveness analysis depend on assumptions about the difference in cost and effect, the standard deviations of cost and effect, the correlation of the difference in cost and effect, the α and β errors and maximum willingness to pay (W). The first seven of these...
Persistent link: https://www.econbiz.de/10010614324
This article deals with the question of how to handle costs to enhance medication adherence in trial-based pharmacoeconomic analyses. It argues that resources to improve patient adherence have a clearly distinguishable impact on costs and utility and thus are relatively easy to exclude when...
Persistent link: https://www.econbiz.de/10010614359
Comparative effectiveness research (CER) is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat and monitor a clinical condition, or to improve the delivery of care. The purpose of this article is to compare - within...
Persistent link: https://www.econbiz.de/10010614362
Methods for determining sample size requirements for cost-effectiveness studies are reviewed and illustrated. Traditional methods based on tests of hypothesis and power arguments are given for the incremental cost-effectiveness ratio and incremental net benefit (INB). In addition, a full...
Persistent link: https://www.econbiz.de/10010614384